Zhu Qiuyu Martin, Berry Natalia
Kaiser Permanente Mid-Atlantic States Internal Medicine Residency Program Gaithersburg, MD, US.
Mid-Atlantic Permanente Medical Group McLean, VA, US.
Eur Cardiol. 2023 Sep 28;18:e55. doi: 10.15420/ecr.2023.09. eCollection 2023.
Tricuspid regurgitation (TR) is a relatively common finding. There has been growing recognition of the morbidity and adverse prognosis of severe TR, which affects 1.6 million people in the US. However, symptomatic TR remains undertreated despite emerging therapeutic modalities. In this review, the pathophysiological and epidemiological features of TR are examined and the diagnosis, natural history, and clinical presentation are discussed. An overview of TR therapy is provided, including medical and surgical treatments, as well as novel percutaneous approaches. The currently available studies on percutaneous therapy demonstrate promise for transcatheter valve repair and replacement with favourable clinical outcomes and short-term durability. However, further study is needed.
三尖瓣反流（TR）是一种相对常见的情况。人们越来越认识到严重TR的发病率和不良预后，在美国有160万人受其影响。然而，尽管出现了新的治疗方式，有症状的TR仍未得到充分治疗。在本综述中，我们研究了TR的病理生理和流行病学特征，并讨论了其诊断、自然病史和临床表现。提供了TR治疗的概述，包括药物和手术治疗以及新的经皮治疗方法。目前关于经皮治疗的研究表明，经导管瓣膜修复和置换具有良好的临床效果和短期耐久性，颇具前景。然而，仍需进一步研究。
